Back to Peptipedia
Growth HormonePreclinical

IGF-1 LR3

Long R3 insulin-like growth factor I

IGF-1 LR3 is a modified IGF-I analogue used experimentally. The captured source is a cell study, not treatment in people.

Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.

Research areas

Source-based short profile

Evidence matrix

Molecular identity
Confirmed

LR3-IGF-I is the IGF-I analogue named in the cited cell study. It is not interchangeable with native IGF-1, mecasermin or unspecified commercial products.

Human research
None
Replication
Single research group
Clinical endpoints
No clinical endpoints
Safety
Not adequately studied
Approval
No documented approval

The dimensions are presented separately and are not combined into an overall score.

What the source shows

Cultured human skin fibroblasts were studied outside the body; the source provides no clinical efficacy or safety assessment.

Research gaps

  • ·Evidence for native IGF-1 or approved mecasermin must not be transferred to LR3. Clinical pharmacokinetics and benefit are absent.
  • ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.